Zacks Investment Research upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a hold rating to a buy rating in a research report released on Friday. They currently have $3.75 price target on the biotechnology company’s stock.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
A number of other equities analysts have also weighed in on the stock. HC Wainwright set a $6.00 price objective on shares of ZIOPHARM Oncology and gave the stock a buy rating in a report on Tuesday, November 13th. Raymond James upgraded shares of ZIOPHARM Oncology from a market perform rating to an outperform rating and set a $5.00 price objective for the company in a report on Thursday, November 15th. Finally, BidaskClub upgraded shares of ZIOPHARM Oncology from a strong sell rating to a sell rating in a report on Saturday, November 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. ZIOPHARM Oncology has an average rating of Buy and an average target price of $4.92.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Sell-side analysts expect that ZIOPHARM Oncology will post -0.51 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace LLP purchased a new stake in ZIOPHARM Oncology during the 3rd quarter valued at $115,000. Jane Street Group LLC purchased a new stake in ZIOPHARM Oncology during the 3rd quarter valued at $161,000. Raymond James & Associates raised its stake in ZIOPHARM Oncology by 168.3% during the 2nd quarter. Raymond James & Associates now owns 58,290 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 36,568 shares during the last quarter. MetLife Investment Advisors LLC raised its stake in ZIOPHARM Oncology by 77.1% during the 2nd quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock valued at $199,000 after buying an additional 28,734 shares during the last quarter. Finally, Belpointe Asset Management LLC purchased a new stake in ZIOPHARM Oncology during the 3rd quarter valued at $262,000. Institutional investors and hedge funds own 40.07% of the company’s stock.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Recommended Story: Is a Roth IRA right for you?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.